Greenup Street Wealth Management LLC Makes New Investment in DexCom, Inc. $DXCM

Key Points

• Greenup Street Wealth Management LLC established a new position in DexCom in Q4, purchasing 34,043 shares worth approximately $2.26 million.
• DexCom beat Q4 estimates with $0.68 EPS (vs. $0.65 expected) and reported $1.26 billion in revenue, up 13.1% year‑over‑year, while analysts forecast about $2.03 EPS for the current year.
• Market sentiment is broadly positive—DexCom has a consensus Moderate Buy rating with an average target of $86.50, and institutional investors own roughly 97.75% of the stock.

Greenup Street Wealth Management LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 34,043 shares of the medical device company's stock, valued at approximately $2,259,000.

A number of other large investors have also recently modified their holdings of DXCM. SJS Investment Consulting Inc. boosted its position in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company's stock valued at $26,000 after acquiring an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new stake in shares of DexCom during the 3rd quarter valued at about $29,000. CVA Family Office LLC boosted its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company's stock valued at $30,000 after acquiring an additional 147 shares during the last quarter. ORG Partners LLC boosted its position in shares of DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company's stock valued at $34,000 after acquiring an additional 281 shares during the last quarter. Finally, Spire Wealth Management boosted its position in shares of DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company's stock valued at $38,000 after acquiring an additional 305 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

DexCom Price Performance

Shares of DexCom stock opened at $64.02 on Friday. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The company has a market cap of $24.64 billion, a PE ratio of 30.49, a P/E/G ratio of 1.25 and a beta of 1.55. The business has a 50 day moving average of $68.20 and a 200 day moving average of $66.90. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.03. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm's revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.45 earnings per share. As a group, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of research analyst reports. Evercore upgraded DexCom from an "in-line" rating to an "outperform" rating and set a $90.00 price target for the company in a research report on Tuesday, March 24th. Canaccord Genuity Group set a $95.00 target price on DexCom and gave the stock a "buy" rating in a research report on Friday, February 13th. Weiss Ratings upgraded DexCom from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, March 4th. Citigroup boosted their target price on DexCom from $77.00 to $84.00 and gave the stock a "buy" rating in a research report on Wednesday, March 11th. Finally, Barclays restated an "underweight" rating and issued a $72.00 target price (up from $71.00) on shares of DexCom in a research report on Friday, February 13th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and a consensus target price of $86.50.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the company's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $64.85, for a total transaction of $110,245.00. Following the completion of the transaction, the executive vice president owned 112,904 shares in the company, valued at $7,321,824.40. This represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.32% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.